Compass Therapeutics, Inc. (NASDAQ:CMPX) announced statistically significant topline data on Tuesday on the primary efficacy endpoint for COMPANION-002, the company’s ongoing Phase 2/3 trial of ...
A small, seemingly unprepossessing device—a compass four and a half inches in diameter—testifies to a story of war and remembrance, resolve and survival. The artifact is one among scores ...
Compass Therapeutics, Inc. (NASDAQ:CMPX) announced statistically significant topline data on Tuesday on the primary efficacy endpoint for COMPANION-002, the company’s ongoing Phase 2/3 trial of ...